Business Context and Reporting Period
Company: Cooper-Standard Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2025
Principal Executive Offices: Northville, Michigan
This filing reports the entry into a material definitive agreement regarding the company's poison pill defense mechanism (Section 382 Rights Agreement).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action and does not contain financial performance data.
Material Changes
- Extension of Rights Agreement: The Company entered into the First Amendment to its Section 382 Rights Agreement.
- Expiration Date Change: The Final Expiration Date of the rights was extended from November 6, 2025, to November 5, 2026.
- Scope of Change: Except for the extension of the expiration date, the Rights Agreement remains unmodified.
Management Commentary and Risks
Management Rationale: The Board of Directors determined that extending the Final Expiration Date is in the best interests of the Company and its stockholders.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond the standard implications of maintaining a shareholder rights plan. The full text of the amendment is incorporated by reference as Exhibit 4.1.
Investor Verification Checklist
- Verify the terms of the First Amendment to the Section 382 Rights Agreement filed as Exhibit 4.1.
- Confirm the new Final Expiration Date of November 5, 2026, for the Preferred Stock Purchase Rights.
- Review the original Rights Agreement dated November 7, 2022, to understand the baseline terms that remain in effect.